Advancing your gene and cell therapies with novel gene delivery technologies
Effective gene delivery systems and viral vector development are crucial aspects of bringing a new gene or cell therapy (GCT) to market. Our gene delivery platforms support innovators in gene therapy, cell therapy, and vaccination using viral vectors to deliver therapeutic genes to their specific target, helping to improve the efficacy and safety of therapeutic products.
Our strong IP portfolio across lentiviral vectors, AAVs, and adenoviruses supports the entire GCT value chain from discovery to commercialization and is accessible to industrial partners and academic institutions at the forefront of the gene and cell therapy revolution.
Our LentiBOOST™ technology is being used in:
- 40 active clinical trials
- 2 approved therapies
Revvity’s gene delivery team, where SIRION Biotech’s expertise lives on, has many years of experience in collaborating with clients in the gene and cell therapy space on their journey towards market success.
Join our global network of licensees and collaborators to benefit from our deep expertise and proprietary gene delivery technologies.
Please contact us if you’d like to speak to our expert team and learn more about our Gene Delivery licensing portfolio.
For research use only. Not for use in diagnostic procedures.
Explore our gene delivery technologies
AAV Vector Technologies
- AAV capsid evolution using advanced AAV mRNA expression libraries and bioinformatics.
- Direct AAV nanobody targeting technologies for improved localized and systemic vector delivery.
- AAV therapeutic expression cassette development for high-throughput lead vector identification.
Lentiviral Vector Technologies
- LentiBOOST transduction enhancer for improving lentiviral transduction efficiency and increasing vector copy number (VCN), reducing the vector amounts required, lowering manufacturing costs.
- Lentiviral retargeting surface modification technology for directing vectors to specific molecular targets.
- Preclinical lentiviral backbone optimized with increased packaging capacity, helping to shuttle therapeutic transgenes safely and efficiently into the therapeutic target cell.
- Lentiviral therapeutic expression cassette development for high-throughput lead vector identification.
Adenoviral Vector Technologies
- Adenoviral Vector Technologies including our proprietary adenoviral vector Ad19a/64 plus technologies such as BAC for the facilitated generation and manufacturing of recombinant adenoviral particles.
- AdenoBOOST™ Transduction Enhancer: The agent specifically bridges the adenovirus surface to the cell membrane, leading to increased transduction efficiency.
